ROZEL 60MG
Description :
Rozel 60mg belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors and is being examined in multiple clinical trials for the inhibition and treatment of bone metastases. Chemically, it exists of 2 heavy and 2 light chains.
Rozel prescribed for :
Treatment for patients with increase bone mass in men at more risk for fracture getting androgen deprivation therapy for non-metastatic prostate cancer.
Treatment for patients having to increase bone mass in women at more risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
Drug Interaction :
No formal drug-drug interaction with denosumab during trials.
When interacting with some anticancer drug, orthopedic drugs, vaccines will lead to risk of adverse effects can be increased.
When interacting with some anticancer drug, orthopedic drugs, vaccines will lead to risk of adverse effects can be increased.
Dosage Administration :
For adult :
Osteoporosis :
60mg SC (subcutaneously) once every 6 months
Injection of drug should be done in upper arm, upper thigh or abdomen
Giant Cell Tumor of bone :
120mg SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment
Injection of drug should be done in upper arm, upper thigh or abdomen
Osteolytic Bone Metastases of Solid Tumors :
120mg subcutaneously every 4 weeks
Injection of drug should be done in upper arm, upper thigh or abdomen
Hypercalcemia :
120mg subcutaneously every 4 weeks
Injection of drug should be done in upper arm, upper thigh or abdomen
Dosage and administration in pediatric :
13 years and older and 45kg or more
Giant Cell Tumor of bone:
Dose of 120mg Rozel tablet given SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment.
Osteoporosis :
60mg SC (subcutaneously) once every 6 months
Injection of drug should be done in upper arm, upper thigh or abdomen
Giant Cell Tumor of bone :
120mg SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment
Injection of drug should be done in upper arm, upper thigh or abdomen
Osteolytic Bone Metastases of Solid Tumors :
120mg subcutaneously every 4 weeks
Injection of drug should be done in upper arm, upper thigh or abdomen
Hypercalcemia :
120mg subcutaneously every 4 weeks
Injection of drug should be done in upper arm, upper thigh or abdomen
Dosage and administration in pediatric :
13 years and older and 45kg or more
Giant Cell Tumor of bone:
Dose of 120mg Rozel tablet given SC, every 4 weeks with additional 120mg doses on days 8 and 15 of the 1st month treatment.
PRECAUTION :
• Rozel tablets may improve the negative effects of immuno-suppressants. Especially the risk for serious infections may be increased. Inform your doctor of any immuno-suppressive drugs you early consume.
• Not to receive any type of vaccination without your doctor’s consultation while admonishing denosumab.
• Use in pregnancy only if benefit to mother outweighs risk to fetus. Consult with doctor before the treatment
• During Rozel treatment do not breastfeed your infants.
• Not to receive any type of vaccination without your doctor’s consultation while admonishing denosumab.
• Use in pregnancy only if benefit to mother outweighs risk to fetus. Consult with doctor before the treatment
• During Rozel treatment do not breastfeed your infants.
LACTATION :
Rozel 60mg is excreted into human milk is not known. Since possible for severe side effects occurs in nursing infants from Rozel 60mg injection, a decision should be considered that to discontinue nursing or discontinue the drug by giving preference of the importance of the drug to the mother.
For More Information :
Call us : +91–9987711567
Mail to : applepharmaceuticals@gmail.com
Comments
Post a Comment